ZIANA Drug Patent Profile

When do Ziana patents expire, and what generic alternatives are available?

Ziana is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in ZIANA is clindamycin phosphate; tretinoin. There are fifty-five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the clindamycin phosphate; tretinoin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ziana

A generic version of ZIANA was approved as clindamycin phosphate; tretinoin by ACTAVIS MID ATLANTIC on June 12^th, 2015.

Summary for ZIANA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	23
Drug Prices:	Drug price information for ZIANA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZIANA
What excipients (inactive ingredients) are in ZIANA?	ZIANA excipients list
DailyMed Link:	ZIANA at DailyMed

See drug prices for ZIANA

Pharmacology for ZIANA

Drug Class	Lincosamide Antibacterial Retinoid
Physiological Effect	Decreased Sebaceous Gland Activity Neuromuscular Blockade

Paragraph IV (Patent) Challenges for ZIANA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZIANA	Gel	clindamycin phosphate; tretinoin	1.2%/0.025%	050802	1	2010-12-17

US Patents and Regulatory Information for ZIANA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	ZIANA	clindamycin phosphate; tretinoin	GEL;TOPICAL	050802-001	Nov 7, 2006	AB1	RX	Yes	Yes

Expired US Patents for ZIANA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	ZIANA	clindamycin phosphate; tretinoin	GEL;TOPICAL	050802-001	Nov 7, 2006
Bausch	ZIANA	clindamycin phosphate; tretinoin	GEL;TOPICAL	050802-001	Nov 7, 2006
Bausch	ZIANA	clindamycin phosphate; tretinoin	GEL;TOPICAL	050802-001	Nov 7, 2006

International Patents for ZIANA

See the table below for patents covering ZIANA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2063576	VEHICULES A LIBERATION LENTE SERVANT A REDUIRE AU MINIMUM L'IRRITATION CUTANEE DUE A DES COMPOSITIONS TOPIQUES (SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS)
Germany	69029804
European Patent Office	0481007	VEHICULES A LIBERATION LENTE REDUISANT AU MINIMUM L'IRRITATION DERMIQUE DUE A DES COMPOSITIONS A USAGE LOCAL contenant des rétinoides (SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS containing retinoids)
World Intellectual Property Organization (WIPO)	9014833

Supplementary Protection Certificates for ZIANA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1304992	C300617	Netherlands		PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
1304992	PA2013025	Lithuania		PRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
1304992	1390049-3	Sweden		PRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322
1304992	92401	Luxembourg		PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE

Ziana (clindamycin phosphate 1.2% and tretinoin 0.025%) market dynamics and financial trajectory: exclusivity, competitive pressure, and revenue outlook

Last updated: July 7, 2026

Ziana’s commercial trajectory is defined by: (1) a long runway since approval, (2) generic and private-label encroachment risk for an established topical acne fixed-dose combination, and (3) a narrow US market presence relative to dominant acne brands. With no recent signals of broad category growth offsets and ongoing price pressure in topical acne, Ziana’s financial profile tracks “late-cycle” specialty-generic dynamics rather than “new launch” momentum.

---

What is Ziana and how big is the US topical acne opportunity it targets?

Ziana is a topical fixed-dose combination for acne vulgaris containing:

• clindamycin phosphate 1.2% (topical antibiotic)
• tretinoin 0.025% (topical retinoid)

Where Ziana fits in topical acne prescribing

Topical acne therapy splits into:

• retinoids (tretinoin/adapalene/tazarotene)
• topical antibiotics (clindamycin/erythromycin)
• benzoyl peroxide combinations
• fixed-dose antibiotic + retinoid combinations (Ziana’s class)

Ziana’s value proposition is convenience and adherence versus separate products.

Market dynamics shaping demand

Key demand drivers for fixed-dose topical acne combinations:

• prescribing preference shifts toward once-daily retinoids and non-antibiotic regimens
• antibiotic stewardship and resistance concerns affect long-term use of topical antibiotics
• payer and PBM step edits for branded fixed-dose combinations
• generic pricing pressure for both components and for the fixed combination itself where available

---

What is the Orange Book status of Ziana (patents listed and exclusivity posture)?

Ziana’s exclusivity and patent posture is central because it determines whether FDA-approved generics can legally enter via Section 505(b)(2) or ANDA, and whether “authorized generic” strategies are available.

Orange Book framework that determines entry risk

For Ziana, market timing is governed by:

• patent term expiration for active-ingredient and formulation patents
• expiration of any exclusivity tied to the NDA and changes in labeling
• any listed patents covering fixed-dose combinations, specific strengths, formulation characteristics, or use instructions

Market-impact linkage: once listed patents expire (or are cleared through settlement or litigation outcomes), generic entry shifts from “infringement risk” to routine ANDA launch mechanics, compressing net price.

---

When does Ziana lose exclusivity and what generic entry risks exist?

Ziana is an established topical acne product. For late-cycle assets of this type, generic entry risks typically show up via:

• ANDAs filed after patent expiration windows close
• “skin” of the business shifting to lower-cost generics and authorized generics at PBMs
• parallel replacement by multi-brand retinoid-first strategies

Typical generic entry pattern for topical fixed-dose products

In acne fixed combinations, generic risk increases when:

• fixed-dose formulation patents expire
• formulation process patents expire
• method-of-use patents (if any) are narrow or are cleared
• Orange Book listings are no longer blocking

Financial effect of entry

Once a topical fixed-dose combination faces generic substitution:

• gross-to-net declines via mandatory discounts
• market share erodes fast through PBM formulary placement
• sales concentrate among the lowest-cost equivalents and private label in some channels

---

What patents protect Ziana formulations and how many claims drive enforceability?

For Ziana, patent protection relevant to enforceability typically clusters into:

• formulation patents covering gel/vehicle properties and stability
• combination patents covering fixed-dose pairing and/or dosing regimen
• method-of-use patents tied to acne indication instructions

Patent estate structure that matters commercially

In topical acne combination products, claims that most affect generic design-arounds are usually:

• composition-of-matter or formulation-specific limitations
• stability and release parameters tied to shelf life and drug delivery
• packaging or process parameters (less often decisive than composition, but still relevant)

Business implication: if the estate is narrow or already expired, Ziana faces fast erosion; if it still has active formulation coverage, generics can face partial design-around or settlement.

---

Which companies are challenging Ziana and what Paragraph IV filings have occurred?

Paragraph IV challenges are the key market-structure event that triggers:

• 30-month stay (if applicable)
• settlement licensing arrangements
• partial at-risk launches after stay expiration or after favorable court rulings

Market-impact linkage: a successful Paragraph IV posture generally accelerates generic entry and steepens the revenue decline slope.

---

What patent litigation affects Ziana, and do any settlements change launch timing?

Patent litigation outcomes control:

• whether generics delay launch
• whether a generic competitor receives a licensed “authorized” launch
• whether multiple products are tied together through a global settlement

How litigation outcomes translate to financial trajectory

For late-cycle topical branded products:

• a settlement that permits earlier generic launch typically compresses branded net revenue quickly
• a win that blocks all ANDA launches delays price erosion and extends margin

---

How does Ziana compare with other acne fixed-dose and retinoid strategies on market dynamics?

Ziana sits in a competitive set that affects prescribing, payer coverage, and substitution.

Competitive comparisons that drive share shifts

Ziana’s competitive landscape includes:

• topical retinoid monotherapies (adapalene-based regimens)
• antibiotic-retinoid combinations (where available)
• benzoyl peroxide and antibiotic combination regimens
• fixed-dose triple regimens in some markets

Clinical-policy dynamics

Market share is affected by:

• clinician preference for retinoid-based maintenance with intermittent antibiotic courses
• guideline emphasis on limiting antibiotic duration
• payer formularies that steer toward lower-cost retinoids with separate generic antibiotics rather than fixed-dose branded combinations

Net effect: even absent direct generic of Ziana, competitive substitution can reduce demand.

---

What formulations of Ziana exist, and do they change risk or revenue exposure?

Ziana is sold as a fixed-dose topical gel. Revenue exposure and generic risk depend on:

• strength-specific coverage
• formulation-specific patents
• packaging and stability constraints that constrain generic “bioequivalence to the same product”

If patents cover only certain presentation elements, generics may enter through product variations not protected by claims.

---

What manufacturing and IP barriers could slow generic entry for Ziana?

Generic entry barriers for topical fixed-dose products are commonly practical rather than purely patent-driven:

• vehicle composition consistency and stability requirements
• bioavailability considerations are usually less complex than systemic products, but product equivalence remains important
• manufacturing process validation for semisolid gels and uniformity

If the Ziana formulation estate is weak or expired, practical barriers become the main constraint, which typically limits only initial volumes, not the eventual launch.

---

What is Ziana’s FDA regulatory pathway profile and how does that affect competition?

Ziana’s competition typically enters via:

• ANDA for generics when patents are cleared
• 505(b)(2) where alternative pathway leveraging published literature and/or bridging studies is feasible

For customers, regulatory pathway choices determine:

• speed of entry
• strength of data package required
• labeling alignment and substitution acceptance at pharmacies

---

What is Ziana’s financial trajectory: revenue trend, margin pressure, and buyer economics?

Ziana’s financial trajectory is consistent with:

• branded topline declining as fixed-dose combinations face substitution and step therapy
• margin pressure from PBM contracting, rebates, and increased gross-to-net
• limited upside unless an exclusivity extension, dominant formulary placement, or new indication materially expands demand

Late-cycle branded profile

Typical drivers of Ziana’s late-cycle revenue profile:

• increased generic availability across components and fixed-dose equivalents
• shift of acne treatment patterns toward retinoid-centric regimens
• discounting to retain payer access
• channel migration to lower-cost substitutes

Commercial bottom line: Ziana is positioned for ongoing net revenue compression rather than growth, unless protected by still-active listings or a narrow settlement that delays full competitive entry.

---

Key timeline: how to map exclusivity, patent expiry, litigation, and generic entry to revenue

The market timeline for Ziana should be tracked in this order:

1. patent term expirations for formulation and combination patents
2. FDA regulatory clearances for ANDA approval (post-litigation or after patent expiry)
3. launch of first generic or authorized generic
4. PBM formulary updates and rebate re-benchmarking
5. branded share loss and net price compression

Business use: build a revenue bridge model that links net sales decline to the generic entry date and the subsequent PBM coverage change cycle.

---

What does this mean for valuation, licensing, and R&D decisions tied to topical acne combos?

For licensing or portfolio decisions, Ziana-like assets should be evaluated on:

• remaining active patent term (if any) and enforceability strength
• whether the product is replaceable at the payer level via separate generics for antibiotic + retinoid
• strength of the formulation IP relative to generic design-around feasibility
• probability of litigation outcomes that accelerate or delay entry

Actionable competitive posture

• If patent protection is largely expired, expect faster substitution and smaller incremental gains from brand relaunch efforts.
• If an active formulation or combination patent remains, competitor entry timing is the key variable, with settlement probability rising as court schedules converge.

---

Key Takeaways

• Ziana is a fixed-dose topical acne combination (clindamycin 1.2% and tretinoin 0.025%) with a late-cycle market dynamic dominated by substitution risk and PBM price pressure.
• Financial trajectory is characterized by gross-to-net compression and market share erosion once fixed-dose combination exclusivity and listings clear.
• Competitive forces include antibiotic stewardship trends and retinoid-first prescribing, not only direct generic substitution.
• Patent and Orange Book status are the critical determinants of generic entry timing and the slope of branded revenue decline.

---

FAQs

1. How do PBM step edits usually affect branded topical acne fixed-dose combinations like Ziana?
2. Do generic clindamycin-tretinoin combinations typically substitute at the pharmacy level without prescriber involvement?
3. What kinds of formulation patent claims most often block generic topical gels?
4. How do antibiotic stewardship guideline changes shift demand away from topical antibiotic-retinoid fixed-dose products?
5. What settlement structures are most common when Paragraph IV challenges resolve for topical combination acne drugs?

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. U.S. FDA. Drugs@FDA: Ziana (clindamycin phosphate and tretinoin) drug label and regulatory history.